Not a traditional drug phase: testing 68-Gallium Dotatate for Hurthle Cell Thyroid Cancer
Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer.
Official registry: https://clinicaltrials.gov/study/NCT00001160 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · enrollment listed as 2,500
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 2,500 people at Bethesda. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Studies on Thyroid Nodules and Thyroid Cancer
Interventions: 68-Gallium Dotatate
Primary outcome (registry wording): Evaluation of thyroid cancer
Who it is for (from inclusion criteria)
- Ages 6 Months to 98 Years
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male or female, adults or children \>= 6 months+
- Patients with known or suspected thyroid nodules and/or thyroid cancer
- At risk family members of patients who have a genetic susceptibility to developing thyroid cancer
Who the registry excludes
- An individual who meets any of the following criteria will be excluded from participation in this study:
- 1\. Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma requiring intervention before thyroid cancer is addressed
Public study contact (from the registry)
Padmasree Veeraraghavan, R.N.
padmasree.veeraraghavan@nih.gov
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- National Institutes of Health Clinical Center — Bethesda, Maryland (recruiting)
FAQ about this NCT record
Is NCT00001160 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT00001160?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT00001160?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary